Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Roche, the Swiss pharmaceutical giant, has discontinued development of a potentially important diabetes drug, a move that could raise new safety questions about the entire category of drugs, which includes the controversial diabetes medicine Avandia.
Roche said Wednesday that a safety monitoring committee had recommended halting a late-stage clinical trial of the drug, aleglitazar, because of ?safety signals and lack of efficacy.? The company said that it decided to halt that study and all others involving the drug.
?We are disappointed by this outcome as we hoped that aleglitazar would provide significant benefit for patients with Type 2 diabetes who are at risk of cardiovascular disease,? Dr. Hal Barron, the chief medical officer, said in a statement.
http://www.nytimes.com/2013/07/11/business/roche-abandons-new-diabetes-drug.html
Roche said Wednesday that a safety monitoring committee had recommended halting a late-stage clinical trial of the drug, aleglitazar, because of ?safety signals and lack of efficacy.? The company said that it decided to halt that study and all others involving the drug.
?We are disappointed by this outcome as we hoped that aleglitazar would provide significant benefit for patients with Type 2 diabetes who are at risk of cardiovascular disease,? Dr. Hal Barron, the chief medical officer, said in a statement.
http://www.nytimes.com/2013/07/11/business/roche-abandons-new-diabetes-drug.html